SSSW(SH:688399)2026-01-30 09:20Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -29.4 million and -44 million yuan, representing an increase in losses of 27.4 million to 41.99 million yuan compared to the previous year [3]. - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -81.9 million and -122.8 million yuan, indicating an increase in losses of 10.06 million to 50.96 million yuan compared to the previous year [6]. - In 2024, the company reported a total profit of 4.1872 million yuan, with a net profit attributable to shareholders of the parent company of -0.2 million yuan [7]. Business Operations - The company has maintained stable development in its main business, but revenue from self-produced diagnostic reagents has declined due to intensified industry competition and ongoing medical procurement [8]. - The company has reduced the balance of long-aged accounts receivable through increased collection efforts, leading to a decrease in impairment provisions compared to the previous year [8]. Research and Development - The company has focused on R&D investments, maintaining a relatively high intensity of R&D spending despite a year-on-year decrease, and is enhancing its core product line and overall solution capabilities [10]. Government Support - The company has experienced a reduction in government subsidies received during the reporting period [10]. Earnings Forecast - The company has not identified any significant uncertainties that would affect the accuracy of this earnings forecast [11]. - The forecast data is preliminary and the final audited financial data will be disclosed in the 2025 annual report [12].